Production (Stage)
TG Therapeutics, Inc.
TGTX
$34.57
$0.330.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 147.26% | 261.84% | -96.59% | 114.45% | 72.71% |
| Total Depreciation and Amortization | -72.41% | -76.32% | -84.93% | -40.63% | -57.35% |
| Total Amortization of Deferred Charges | -49.13% | -48.55% | -32.51% | 0.00% | 34.63% |
| Total Other Non-Cash Items | 83.61% | 33.73% | 67.38% | -34.05% | 10.94% |
| Change in Net Operating Assets | -700.08% | -654.44% | 20.65% | -30.44% | 78.58% |
| Cash from Operations | -249.88% | -94.10% | -114.58% | 113.18% | 86.30% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -39.48% | 135.32% | 69.20% | -94.21% | -50.05% |
| Cash from Investing | -39.75% | 135.28% | 69.12% | -94.21% | -50.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 110.00% | -- | -52.73% | -99.71% | -97.25% |
| Repurchase of Common Stock | -- | -661,000.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -61,120.00% | -607,100.00% | 31,836.82% | -99.71% | -99.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -173.61% | 72.53% | 109.51% | -79.08% | 57.26% |